CD44 and neoplasm: Al-Hajj demonstrated that antibodies to the CD44 and CD24 cell surface antigens in combination with fluorescence-activated cell sorting (FACS) separated breast tumor cells into BTIC-enriched (CD44+/CD24−) and BTIC-depleted fractions as assessed by tumor cell transplantation into immune-compromised mice [1].